Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for FG-3246 (ADC) in Cancer, Castration-resistant prostate cancer. The expected timing is based on the latest available company guidance and may change.
4/2/24- Topline data reported. 3/17/25- Initiate Ph2 study by mid-2025. 9/24/25- Ph2 trial initiated. Interim analysis expected in H2 2026. 11/10/25:- Interim results from the ongoing Phase 2 monotherapy trial in metastatic castration-resistant prostate cancer remain expected in H2 2026. 02/23/26:- Combo data support FG-3246 efficacy and safety; Phase 2 monotherapy interim analysis remains on track for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.